IP Library Granted Patent US 9,308,209
Granted Patent B2
US 9,308,209 · App. 14/531,888 · Granted Apr 12, 2016

Identification of stabilizers of multimeric proteins

Inventors: Isabella A. Graef (Woodside, CA); Mamoun M. Alhamadsheh (Fremont, CA)
Assignee: The Board of Trustees of the Leland Stanford Junio
A61K31/519A61K31/4196A61K31/428A61K31/433C07D231/12C07D487/04G01N21/6428
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,308,209
App. No.
14/531,888
Granted
Apr 12, 2016
Kind
B2
Abstract

Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and thereby decreasing aggregate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

Claims (29)

1. A method of decreasing TTR amyloid fibril formation, the method comprising contacting TTR with a pharmaceutical composition comprising a compound of formula (XVII):

wherein L is a linker of about 1 to 8 atoms in length;

R 51 and R 52 are selected from an alkyl, an aryl, an alkoxy, an aryloxy, a hydroxyl, a heterocyclic group, a halo, a nitro and a cyano;

R 53 is selected from hydrogen, an alkyl, an aryl and a heterocyclic group; and

R 54 is an aryl group,

wherein the contacting decreases TTR amyloid fibril formation.

2. The method of claim 1 , wherein the composition further comprises at least one of a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a pharmaceutically acceptable excipient and a pharmaceutically acceptable adjuvant.

3. The method of claim 1 , wherein the composition does not contain detectable dimethyl sulfoxide.

4. The method of claim 1 , wherein the compound is of the structure of Formula XVIII:

wherein n is 1, 2, 3 or 4;

R 55 , R 56 , and R 57 are as defined above for R 51 , R 52 , and R 53 ; and

R 58 is selected from an aryl, an aryloxy and a heterocyclic group.

5. The method of claim 4 , wherein R 58 has the structure:

6. The method of claim 4 , wherein:

n is 2 or 3;

R 55 and R 56 are methyl;

R 57 is hydrogen; and

R 58 is selected from an aryl, an aryloxy and a heterocyclic group.

7. The method of claim 1 , wherein the compound is of the structure of one of formulas XIX and XX:

wherein L is a linker of of about 1 to 8 atoms in length;

n is 1, 2, 3 or 4;

R 61 and R 62 are selected from hydrogen, an alkyl, an aryl, an alkoxy, an aryloxy, a hydroxyl, a heterocyclic group, a halo, a nitro and a cyano;

R 63 is selected from hydrogen, an alkyl, an aryl and a heterocyclic group; and

R 64 and R 68 are independently one or more groups, each R 64 and R 68 independently selected from an alkyl, an aryl, an alkoxy, an aryloxy, an acetyl, a carboxy, a formyl, an amido, a hydroxyl, a heterocyclic group, a halo, a nitro and a cyano, wherein optionally two or more R 64 or R 68 groups may be cyclically linked.

8. The method of claim 7 , wherein

n is 2 or 3;

R 61 , R 62 , R 65 and R 66 are methyl;

R 63 is R 67 are hydrogen; and

R 64 and R 67 are independently selected from an aryl, an aryloxy and a heterocyclic group.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2015
From: GRAEF, ISABELLA A.; ALHAMADSHEH, MAMOUN
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 034739/0183 →
Continuity (3)
Continuation 13696505
Provisional Application 61332638 · May 7, 2010
Related Publication 20150126532A1 · May 7, 2015